High Dimensional Analysis of Immune Cells in Pediatric Patients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age2-18
SponsorSeoul National University Hospital
About this trial
The purpose of this study is to characterize immune cells using single-cell transcriptomic analysis in pediatric patients aged 2 to 18 years undergoing general anesthesia who are expected to receive Rocuronium, a non-depolarizing neuromuscular blocking agent, in the event of an allergic reaction.
Eligibility criteria
Qualifiers
Pediatric patients between the ages of 2 and 18 undergoing general anesthesia and surgery using the neuromuscular blocker, rocuronium.
Disqualifiers
Patients who have received immunomodulators, immunosuppressants, etc.
Patients with autoimmune diseases (rheumatoid arthritis, lupus, Behcet's disease, etc.)
Patients who regularly take, or have taken within 4 weeks, medications that may affect the immune system (oral steroids, anti-inflammatories, etc.)
Other cases where the Principal Investigator determines that it is difficult to conduct the study.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Source ClinicalTrials.gov